The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–289.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Coughlin SS. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat. 2019;177(3):537–548.
   PubMed Web of Science ®Google Scholar
• Ayoub N, Lucas C, Kaddoumi A. Genomics and pharmacogenomics of breast cancer: current knowledge and trends. Asian Pac J Cancer Prev. 2011;12(5):1127–1140.
   PubMedGoogle Scholar
• Stecklein SR, Jensen RA, Pal A. Genetic and epigenetic signatures of breast cancer subtypes. Front Biosci (Elite Ed). 2012;4:934–949.
   PubMedGoogle Scholar
• Sudhakara Prasad K, Cao X, Gao N, et al. A low-cost nanomaterial-based electrochemical immunosensor on paper for high-sensitivity early detection of pancreatic cancer. Sens Actuators B Chem. 2020;305. DOI:10.1016/j.snb.2019.127516.
   PubMed Web of Science ®Google Scholar
• Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52(Pt 1):56–73.
   PubMed Web of Science ®Google Scholar
• Salmaninejad A, Zamani MR, Pourvahedi M, et al. Cancer/Testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. 2016;45(7):619–640.
   PubMed Web of Science ®Google Scholar
• Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015;6(18):15772–15787.
   PubMedGoogle Scholar
• Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615–625.
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–1647.
   PubMed Web of Science ®Google Scholar
• Bode PK, Thielken A, Brandt S, et al. Cancer testis antigen expression in testicular germ cell tumorigenesis. Mod Pathol. 2014;27(6):899–905.
   PubMed Web of Science ®Google Scholar
• Krishnadas DK, Bai F, Lucas KG. Cancer testis antigen and immunotherapy. Immunotargets Ther. 2013;2:11–19.
   PubMedGoogle Scholar
• Meng X, Sun X, Liu Z, et al. A novel era of cancer/testis antigen in cancer immunotherapy. Int Immunopharmacol. 2021;98:107889.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Ono T, Matsushita H, et al. A-kinase anchoring protein 3 messenger RNA expression in ovarian cancer and its implication on prognosis (0020-7136 (Print)). 2004
   Google Scholar
• Hasegawa K, Ono T, Matsushita H, et al. A-kinase anchoring protein 3 messenger RNA expression in ovarian cancer and its implication on prognosis. Int J Cancer. 2004;108(1):86–90.
   PubMed Web of Science ®Google Scholar
• Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153–189.
   PubMed Web of Science ®Google Scholar
• Brandão M, Caparica R, Eiger D, et al. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann Oncol. 2019;30(Suppl_10):x27–x42.
   PubMed Web of Science ®Google Scholar
• Chen L, Wu Q, Xu X, et al. Cancer/testis antigen LDHC promotes proliferation and metastasis by activating the PI3K/Akt/GSK-3β-signaling pathway and the in lung adenocarcinoma. Exp Cell Res. 2021;398(2):112414.
   PubMed Web of Science ®Google Scholar
• Law NC, Donaubauer EM, Zeleznik AJ, et al. How protein kinase a activates canonical tyrosine kinase signaling pathways to promote granulosa cell differentiation. Endocrinology. 2017;158(7):2043–2051.
   PubMed Web of Science ®Google Scholar
• Xu K, Qi H. Sperm-specific AKAP3 is a dual-specificity anchoring protein that interacts with both protein kinase a regulatory subunits via conserved N-terminal amphipathic peptides. Mol Reprod Dev. 2014;81(7):595–607.
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhou X, Peng W, et al. Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer. BMC Cancer. 2021;21(1):1062.
   PubMed Web of Science ®Google Scholar
• Zhang H, Fang Z, Guo Y, et al. Long noncoding RNA SNHG10 promotes colorectal cancer cells malignant progression by targeting miR-3690. Bioengineered. 2021;12(1):6010–6020.
   PubMed Web of Science ®Google Scholar
• Han B, Ge Y, Cui J, et al. Down-regulation of lncRNA DNAJC3-AS1 inhibits colon cancer via regulating miR-214-3p/LIVIN axis. Bioengineered. 2020;11(1):524–535.
   PubMed Web of Science ®Google Scholar
• Kong L, Du W, Cui Z, et al. Expression of lactate dehydrogenase C in MDA‑MB‑231 cells and its role in tumor invasion and migration. Mol Med Rep. 2016;13(4):3533–3538.
   PubMed Web of Science ®Google Scholar
• Cai L, Wang H, Li Q, et al. Salidroside inhibits H2O2-induced apoptosis in PC12 cells by preventing cytochrome c release and inactivating of caspase cascade. Acta Biochim Biophys Sin (Shanghai). 2008;40(9):796–802.
   PubMed Web of Science ®Google Scholar
• Ding X, Xu X, He XF, et al. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling. Bioengineered. 2021;12(1):803–814.
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Curigliano G. Immunotherapy of breast cancer. Prog Tumor Res. 2015;42:30–43.
   PubMed Web of Science ®Google Scholar
• Mahmoud AM. Cancer testis antigens as immunogenic and oncogenic targets in breast cancer. Immunotherapy. 2018;10(9):769–778.
   PubMed Web of Science ®Google Scholar
• Parvizpour S, Razmara J, Pourseif MM, et al. In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens. Bioimpacts. 2019;9(1):45–56.
   PubMed Web of Science ®Google Scholar
• Hamaï A, Duperrier-Amouriaux K, Pignon P, et al. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS One. 2011;6(6):e21129.
   PubMed Web of Science ®Google Scholar
• Sharma VR, Gupta GK, Sharma AK, et al. PI3K/Akt/mTOR intracellular pathway and breast cancer: factors, mechanism and regulation. Curr Pharm Des. 2017;23(11):1633–1638.
   PubMed Web of Science ®Google Scholar
• Song MH, Choi KF, Shin D-H, et al. Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma. (1791-2431 (Electronic). 2012.
   Google Scholar
• Esmaeili R, Majidzadeh AK, Farahmand L, et al. AKAP3 correlates with triple negative status and disease free survival in breast cancer. (1471-2407 (Electronic)). 2015
   Google Scholar
• Gry M, Rimini R, Strömberg S, et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics. 2009;10(1):365.
   PubMed Web of Science ®Google Scholar
• Sharma S, Qian FF, Keitz B, et al. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecol Oncol. 2005 Oct;99(1):183–188.
   PubMed Web of Science ®Google Scholar
• Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35(4):515–524.
   PubMed Web of Science ®Google Scholar
• Cui C, Li S, Wu D. Znhit1 inhibits breast cancer by up-regulating PTEN to deactivate the PI3K/Akt/mTOR pathway. Life Sci. 2019;224:204–211.
   PubMed Web of Science ®Google Scholar
• Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017;45:62–71.
   PubMed Web of Science ®Google Scholar